157 related articles for article (PubMed ID: 3180149)
1. Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Cancer Immunol Immunother; 1988; 27(3):246-54. PubMed ID: 3180149
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells.
Nio Y; Zighelboim J; Berek J; Bonavida B
Cancer; 1989 Jul; 64(2):434-41. PubMed ID: 2736490
[TBL] [Abstract][Full Text] [Related]
4. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
Bonavida B; Tsuchitani T; Zighelboim J; Berek JS
Gynecol Oncol; 1990 Sep; 38(3):333-9. PubMed ID: 2227544
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of human recombinant tumor necrosis factor alone and in combination with other biological response modifiers on human digestive organ cancer xenografts transplanted in nude mice.
Nio Y; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Kawabata K; Masai Y; Tun T; Fukumoto M; Tobe T
Biotherapy; 1991; 3(4):337-44. PubMed ID: 1786197
[TBL] [Abstract][Full Text] [Related]
6. Cytokines and pancreatic cancer. The effect of rIFN-gamma, HuLeIFN, rTNF-alpha, and LAK-cells on pancreatic and other gastrointestinal tumors in vitro.
Kühl JS; Klapdor R; Mohr H; Arps H; Dietel M
Int J Pancreatol; 1989 Mar; 4(2):207-19. PubMed ID: 2498436
[TBL] [Abstract][Full Text] [Related]
7. Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells.
Nio Y; Zighelboim J; Berek J; Bonavida B
Cancer Chemother Pharmacol; 1990; 26(1):1-8. PubMed ID: 2322985
[TBL] [Abstract][Full Text] [Related]
8. Activation of human peripheral blood-derived monocytes by OK-432 (Streptococcus pyogenes): augmented cytotoxicity and secretion of TNF and synergy with rIFN-gamma.
Bonavida B; Jewett A
Cell Immunol; 1989 Oct; 123(2):373-83. PubMed ID: 2507170
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic effects of tumor necrosis factor alone and in combination with gamma-interferon on tumor biopsies in clonogenic assay.
Salmon SE; Young L; Scuderi P; Clark B
J Clin Oncol; 1987 Nov; 5(11):1816-21. PubMed ID: 3119787
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
11. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
[TBL] [Abstract][Full Text] [Related]
12. Activated monocytes kill malignant brain tumor cells in vitro.
Kirsch M; Fischer H; Schackert G
J Neurooncol; 1994; 20(1):35-45. PubMed ID: 7807182
[TBL] [Abstract][Full Text] [Related]
13. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
14. Treatment with biologic response modifiers in patients with ovarian cancer.
Koelbl H; Micksche M; Gitsch G; Hanzal E; Nowotny C
Eur J Obstet Gynecol Reprod Biol; 1991 Aug; 41(1):64-9. PubMed ID: 1748228
[TBL] [Abstract][Full Text] [Related]
15. Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan.
Ishihara K; Hayasaka K; Yamazaki N
J Invest Dermatol; 1989 May; 92(5 Suppl):326S-328s. PubMed ID: 2469742
[TBL] [Abstract][Full Text] [Related]
16. Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifiers of bacterial origin.
Satoh M; Inagawa H; Shimada Y; Soma G; Oshima H; Mizuno D
J Biol Response Mod; 1987 Oct; 6(5):512-24. PubMed ID: 2445926
[TBL] [Abstract][Full Text] [Related]
17. TNF induces endogenous TNF in vivo: the basis of EET therapy as a combination of rTNF together with endogenous TNF.
Inagawa H; Oshima H; Soma G; Mizuno D
J Biol Response Mod; 1988 Dec; 7(6):596-607. PubMed ID: 3216223
[TBL] [Abstract][Full Text] [Related]
18. Studies on in vitro mechanisms of anti-tumor activity of the tumor necrosis factor alpha against human renal carcinoma cell line (KU-2).
Shibayama T
Keio J Med; 1989 Mar; 38(1):13-26. PubMed ID: 2716215
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of the streptococcal preparation OK-432 in a murine model of ovarian cancer.
Lichtenstein A
Cancer Immunol Immunother; 1987; 24(2):172-7. PubMed ID: 3829052
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of induction of endogenous tumor necrosis factor in ascites of ovarian cancer patients by OK-432, a streptococcal preparation.
Mori H; Itoh N; Tamaya T
Immunopharmacol Immunotoxicol; 1989; 11(1):33-53. PubMed ID: 2503555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
